Prestige Consumer Healthcare (NYSE:PBH) Price Target Cut to $72.00 by Analysts at Canaccord Genuity Group

Prestige Consumer Healthcare (NYSE:PBH) had its price objective decreased by Canaccord Genuity Group from $86.00 to $72.00 in a report published on Friday morning,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock.

Several other analysts also recently weighed in on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a report on Tuesday, April 21st. Jefferies Financial Group dropped their target price on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a report on Friday, January 30th. Finally, Oppenheimer downgraded shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a report on Thursday. Two equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $70.75.

Prestige Consumer Healthcare Stock Up 1.7%

Shares of NYSE PBH opened at $46.69 on Friday. The company has a 50 day simple moving average of $57.87 and a 200-day simple moving average of $61.38. The company has a market capitalization of $2.21 billion, a P/E ratio of 11.94, a P/E/G ratio of 1.47 and a beta of 0.40. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.57 and a quick ratio of 1.93. Prestige Consumer Healthcare has a 1 year low of $42.62 and a 1 year high of $89.37.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings results on Wednesday, May 13th. The company reported $1.23 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.39 by ($0.16). The firm had revenue of $281.62 million for the quarter, compared to analyst estimates of $293.64 million. Prestige Consumer Healthcare had a return on equity of 11.54% and a net margin of 17.48%.The firm’s quarterly revenue was down 5.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.32 EPS. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. On average, equities research analysts predict that Prestige Consumer Healthcare will post 4.47 earnings per share for the current year.

Insiders Place Their Bets

In related news, VP Jeffrey Zerillo sold 1,207 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $54.99, for a total value of $66,372.93. Following the completion of the sale, the vice president owned 42,820 shares in the company, valued at approximately $2,354,671.80. This trade represents a 2.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.40% of the company’s stock.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PBH. Norges Bank purchased a new position in Prestige Consumer Healthcare in the 4th quarter valued at approximately $36,954,000. Nordea Investment Management AB boosted its position in Prestige Consumer Healthcare by 547.4% in the 4th quarter. Nordea Investment Management AB now owns 615,215 shares of the company’s stock valued at $37,811,000 after buying an additional 520,186 shares during the period. Brandes Investment Partners LP boosted its position in Prestige Consumer Healthcare by 93.2% in the 4th quarter. Brandes Investment Partners LP now owns 606,737 shares of the company’s stock valued at $37,430,000 after buying an additional 292,744 shares during the period. Capital Research Global Investors boosted its position in Prestige Consumer Healthcare by 107.9% in the 4th quarter. Capital Research Global Investors now owns 561,497 shares of the company’s stock valued at $34,639,000 after buying an additional 291,425 shares during the period. Finally, Squarepoint Ops LLC boosted its position in Prestige Consumer Healthcare by 316.1% in the 3rd quarter. Squarepoint Ops LLC now owns 301,866 shares of the company’s stock valued at $18,836,000 after buying an additional 229,311 shares during the period. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Key Prestige Consumer Healthcare News

Here are the key news stories impacting Prestige Consumer Healthcare this week:

• Negative Sentiment: Prestige reported fiscal Q4 earnings and revenue below expectations, with EPS of $1.23 versus the $1.39 consensus and revenue of $281.6 million versus $292.0 million expected, raising concerns about slower sales momentum and earnings execution. Prestige Consumer Healthcare: Fiscal Q4 Earnings Snapshot
• Negative Sentiment: Several law firms announced securities-fraud investigations into Prestige Consumer Healthcare following the earnings release, which can add overhang and increase investor anxiety around possible disclosure issues. Securities Fraud Investigation Into Prestige Consumer Healthcare (PBH) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
• Negative Sentiment: Canaccord Genuity cut its price target on PBH from $86 to $72, signaling a more cautious view on the company’s outlook even though it kept a Buy rating. Canaccord Genuity price target update
• Negative Sentiment: Oppenheimer downgraded Prestige Consumer Healthcare, adding to the negative analyst reaction after the earnings miss and reinforcing concerns about near-term performance. Oppenheimer downgrades Prestige Consumer Healthcare (PBH)
• Neutral Sentiment: The company’s earnings call and presentation may help investors assess whether management can defend margins and stabilize growth after the weak quarter. Prestige Consumer Healthcare Inc. (PBH) Q4 2026 Earnings Call Transcript

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).